U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Esophageal Adenocarcinoma

MedGen UID:
1779223
•Concept ID:
C5447503
•
Neoplastic Process

Definition

Esophageal adenocarcinoma that is resistant to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory Esophageal Adenocarcinoma

Professional guidelines

PubMed

Camrelizumab and metronomic capecitabine for patients with treatment-refractory solid tumors (McCREST trial).
Zhou C, Shangguan C, Shi M, Xi W, Wu J, Yang H, Guo L, Cai Q, Shi Y, Liu J, Zhang J
Future Oncol 2022 Jul;18(23):2495-2503. Epub 2022 Jun 15 doi: 10.2217/fon-2021-1579. PMID: 35703115
Advances in the treatment of gastric cancer.
Ilson DH
Curr Opin Gastroenterol 2017 Nov;33(6):473-476. doi: 10.1097/MOG.0000000000000395. PMID: 28877045
Current treatment options for esophageal diseases.
Martínek J, Akiyama JI, Vacková Z, Furnari M, Savarino E, Weijs TJ, Valitova E, van der Horst S, Ruurda JP, Goense L, Triadafilopoulos G
Ann N Y Acad Sci 2016 Oct;1381(1):139-151. Epub 2016 Jul 8 doi: 10.1111/nyas.13146. PMID: 27391867

Recent clinical studies

Etiology

Risks and benefits of TIPS in HCC and other liver malignancies: a literature review.
Fichtl A, Seufferlein T, Zizer E
BMC Gastroenterol 2023 Nov 20;23(1):403. doi: 10.1186/s12876-023-03047-0. PMID: 37986043Free PMC Article
CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer.
Janjigian YY, Bendell J, Calvo E, Kim JW, Ascierto PA, Sharma P, Ott PA, Peltola K, Jaeger D, Evans J, de Braud F, Chau I, Harbison CT, Dorange C, Tschaika M, Le DT
J Clin Oncol 2018 Oct 1;36(28):2836-2844. Epub 2018 Aug 15 doi: 10.1200/JCO.2017.76.6212. PMID: 30110194Free PMC Article
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Chen LT
Lancet 2017 Dec 2;390(10111):2461-2471. Epub 2017 Oct 6 doi: 10.1016/S0140-6736(17)31827-5. PMID: 28993052
Current treatment options for esophageal diseases.
Martínek J, Akiyama JI, Vacková Z, Furnari M, Savarino E, Weijs TJ, Valitova E, van der Horst S, Ruurda JP, Goense L, Triadafilopoulos G
Ann N Y Acad Sci 2016 Oct;1381(1):139-151. Epub 2016 Jul 8 doi: 10.1111/nyas.13146. PMID: 27391867
Gastroesophageal reflux disease.
Kahrilas PJ
JAMA 1996 Sep 25;276(12):983-8. PMID: 8805734

Diagnosis

Current treatment options for esophageal diseases.
Martínek J, Akiyama JI, Vacková Z, Furnari M, Savarino E, Weijs TJ, Valitova E, van der Horst S, Ruurda JP, Goense L, Triadafilopoulos G
Ann N Y Acad Sci 2016 Oct;1381(1):139-151. Epub 2016 Jul 8 doi: 10.1111/nyas.13146. PMID: 27391867
Minimally invasive esophagectomy for dysplastic Barrett's esophagus.
Markar SR, Hanna G
World J Surg 2015 Mar;39(3):608-14. doi: 10.1007/s00268-014-2746-1. PMID: 25145822
Management of severe gastroesophageal reflux disease.
DiPalma JA
J Clin Gastroenterol 2001 Jan;32(1):19-26. doi: 10.1097/00004836-200101000-00006. PMID: 11154163
Gastroesophageal reflux disease.
Kahrilas PJ
JAMA 1996 Sep 25;276(12):983-8. PMID: 8805734
Barrett's esophagus: a review.
Sjogren RW Jr, Johnson LF
Am J Med 1983 Feb;74(2):313-21. doi: 10.1016/0002-9343(83)90635-6. PMID: 6337489

Therapy

Immunotherapy in esophagogastric cancer.
Ilson DH
Clin Adv Hematol Oncol 2021 Oct;19(10):639-647. PMID: 34637430Free PMC Article
Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial.
Bardia A, Messersmith WA, Kio EA, Berlin JD, Vahdat L, Masters GA, Moroose R, Santin AD, Kalinsky K, Picozzi V, O'Shaughnessy J, Gray JE, Komiya T, Lang JM, Chang JC, Starodub A, Goldenberg DM, Sharkey RM, Maliakal P, Hong Q, Wegener WA, Goswami T, Ocean AJ
Ann Oncol 2021 Jun;32(6):746-756. Epub 2021 Mar 16 doi: 10.1016/j.annonc.2021.03.005. PMID: 33741442
A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study.
Türeci O, Sahin U, Schulze-Bergkamen H, Zvirbule Z, Lordick F, Koeberle D, Thuss-Patience P, Ettrich T, Arnold D, Bassermann F, Al-Batran SE, Wiechen K, Dhaene K, Maurus D, Gold M, Huber C, Krivoshik A, Arozullah A, Park JW, Schuler M
Ann Oncol 2019 Sep 1;30(9):1487-1495. doi: 10.1093/annonc/mdz199. PMID: 31240302Free PMC Article
CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer.
Janjigian YY, Bendell J, Calvo E, Kim JW, Ascierto PA, Sharma P, Ott PA, Peltola K, Jaeger D, Evans J, de Braud F, Chau I, Harbison CT, Dorange C, Tschaika M, Le DT
J Clin Oncol 2018 Oct 1;36(28):2836-2844. Epub 2018 Aug 15 doi: 10.1200/JCO.2017.76.6212. PMID: 30110194Free PMC Article
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Chen LT
Lancet 2017 Dec 2;390(10111):2461-2471. Epub 2017 Oct 6 doi: 10.1016/S0140-6736(17)31827-5. PMID: 28993052

Prognosis

Risks and benefits of TIPS in HCC and other liver malignancies: a literature review.
Fichtl A, Seufferlein T, Zizer E
BMC Gastroenterol 2023 Nov 20;23(1):403. doi: 10.1186/s12876-023-03047-0. PMID: 37986043Free PMC Article
Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival.
de Klerk LK, Patel AK, Derks S, Pectasides E, Augustin J, Uduman M, Raman N, Akarca FG, McCleary NJ, Cleary JM, Rubinson DA, Clark JW, Fitzpatrick B, Brais LK, Cavanaugh ME, Rode AJ, Jean MG, Lizotte PH, Nazzaro MJ, Severgnini M, Zheng H, Fuchs CS, Enzinger PC, Bass AJ
J Immunother Cancer 2021 Sep;9(9) doi: 10.1136/jitc-2021-002472. PMID: 34593617Free PMC Article
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Chen LT
Lancet 2017 Dec 2;390(10111):2461-2471. Epub 2017 Oct 6 doi: 10.1016/S0140-6736(17)31827-5. PMID: 28993052
Current treatment options for esophageal diseases.
Martínek J, Akiyama JI, Vacková Z, Furnari M, Savarino E, Weijs TJ, Valitova E, van der Horst S, Ruurda JP, Goense L, Triadafilopoulos G
Ann N Y Acad Sci 2016 Oct;1381(1):139-151. Epub 2016 Jul 8 doi: 10.1111/nyas.13146. PMID: 27391867
Gastroesophageal reflux disease.
Kahrilas PJ
JAMA 1996 Sep 25;276(12):983-8. PMID: 8805734

Clinical prediction guides

Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival.
de Klerk LK, Patel AK, Derks S, Pectasides E, Augustin J, Uduman M, Raman N, Akarca FG, McCleary NJ, Cleary JM, Rubinson DA, Clark JW, Fitzpatrick B, Brais LK, Cavanaugh ME, Rode AJ, Jean MG, Lizotte PH, Nazzaro MJ, Severgnini M, Zheng H, Fuchs CS, Enzinger PC, Bass AJ
J Immunother Cancer 2021 Sep;9(9) doi: 10.1136/jitc-2021-002472. PMID: 34593617Free PMC Article
CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer.
Janjigian YY, Bendell J, Calvo E, Kim JW, Ascierto PA, Sharma P, Ott PA, Peltola K, Jaeger D, Evans J, de Braud F, Chau I, Harbison CT, Dorange C, Tschaika M, Le DT
J Clin Oncol 2018 Oct 1;36(28):2836-2844. Epub 2018 Aug 15 doi: 10.1200/JCO.2017.76.6212. PMID: 30110194Free PMC Article
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Chen LT
Lancet 2017 Dec 2;390(10111):2461-2471. Epub 2017 Oct 6 doi: 10.1016/S0140-6736(17)31827-5. PMID: 28993052
Current treatment options for esophageal diseases.
Martínek J, Akiyama JI, Vacková Z, Furnari M, Savarino E, Weijs TJ, Valitova E, van der Horst S, Ruurda JP, Goense L, Triadafilopoulos G
Ann N Y Acad Sci 2016 Oct;1381(1):139-151. Epub 2016 Jul 8 doi: 10.1111/nyas.13146. PMID: 27391867
Gastroesophageal reflux disease.
Kahrilas PJ
JAMA 1996 Sep 25;276(12):983-8. PMID: 8805734

Recent systematic reviews

Toward a Treatment Sequencing Strategy: A Systematic Review of Treatment Regimens in Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma.
Catenacci DV, Chao J, Muro K, Al-Batran SE, Klempner SJ, Wainberg ZA, Shah MA, Rha SY, Ohtsu A, Liepa AM, Knoderer H, Chatterjee A, Van Cutsem E
Oncologist 2021 Oct;26(10):e1704-e1729. Epub 2021 Sep 3 doi: 10.1002/onco.13907. PMID: 34288262Free PMC Article
The integration of immune checkpoint inhibitors with VEGF targeted agents in advanced gastric and gastroesophageal adenocarcinoma: a review on the rationale and results of early phase trials.
Saeed A, Park R, Sun W
J Hematol Oncol 2021 Jan 12;14(1):13. doi: 10.1186/s13045-021-01034-0. PMID: 33436042Free PMC Article
Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma.
Tomita Y, Moldovan M, Chang Lee R, Hsieh AH, Townsend A, Price T
Cochrane Database Syst Rev 2020 Nov 19;11(11):CD012078. doi: 10.1002/14651858.CD012078.pub2. PMID: 33210731Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...